Alkermes (ALKS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Alkermes (ALKS) reported $429.99 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 13.9%. EPS of $1.04 for the same period compares to $0.48 a year ago.The reported revenue represents a surprise of +13.56% over the Zacks Consensus Estimate of $378.63 million. With the consensus EPS estimate being $0.81, the EPS surprise was +28.40%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Alkermes performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Manufacturing and Royalty revenues: $122.26 million compared to the $99.45 million average estimate based on seven analysts. The reported number represents a change of -9.8% year over year. Revenues- Product sales, net: $307.73 million versus the seven-analyst average estimate of $280.13 million. The reported number represents a year-over-year change of +27.2%. Revenues- Proprietary Sales- VIVITROL: $134.13 million versus $107.81 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +31% change. Revenues- Proprietary Sales- ARISTADA: $96.62 million versus $92.56 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +15.9% change. Revenues- Proprietary Sales- LYBALVI: $76.98 million versus $78.60 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +36.9% change. Revenues- Key Commercial Product Revenues- VUMERITY: $34.99 million versus $33.74 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +4.1% change. View all Key Company Metrics for Alkermes here>>>Shares of Alkermes have returned +12.1% over the past month versus the Zacks S&P 500 composite's +4.3% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.Zacks Names #1 Semiconductor StockIt's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alkermes plc (ALKS): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks